October 1, 1996Coronary Artery Disease

Novel nonpeptide antiplatelet glycoprotein llb/llla receptor antagonist, DMP754

View Full Paper

Ask AI

Bookmark

Population

Human platelets, and platelets from mongrel dogs, baboons, sheep, guinea pigs, mice, pigs, rabbits, and…

Design

Preclinical

Authors

SMShaker A. MousaUniversity of North Carolina at Chapel Hill MFMark S. ForsytheDuPont (United States)WLWilliam LorelliDuPont (United States)

Discussion

Member takes

Implication

Supports preclinical advancement of XV459; leaves open translation to clinical antithrombotic benefit in CAD.

Structured PICO

Population

Human platelets (from 12 subjects), and platelets from mongrel dogs, baboons, sheep, guinea pigs, mice, pigs, rabbits, and rats; human and canine liver and plasma esterases.

Intervention

DMP754 (glycoprotein IIb/IIIa antagonist prodrug) and its free acid form XV459

Outcome

Inhibition of platelet aggregation (IC50) and integrin binding affinity/specificitysurrogate

DMP754 and its active form XV459 are potent and highly specific inhibitors of the human platelet GPIIb/IIIa receptor in vitro.

Cite This Study

Mousa et al. (1996) studied this question.

synapsesocial.com/papers/6a82d15c3e02825336d11cf2 https://doi.org/10.1097/00019501-199610000-00010

Topics

Dual antiplatelet therapy

View Full Paper

Ask AI

Bookmark

Novel nonpeptide antiplatelet glycoprotein llb/llla receptor antagonist, DMP754

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Topics

Novel nonpeptide antiplatelet glycoprotein llb/llla receptor antagonist, DMP754

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider